Chardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $12.00 price target on Editas Medicine (NASDAQ: EDIT).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE